EXAS — EXACT Sciences Corporation

EXACT Sciences Corporation (EXAS) is a diagnostics & research company listed on NASDAQ. It is led by Kevin T. Conroy J.D., based in 5505 Endeavor Lane, Madison, WI, United States, 53719, with about 7,100 employees. Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. It offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer; Cologuard Plus Tests; Cancerguard Test; and Genetic Testing. The company also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; Oncodetect Test;OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Riskguard Test, a hereditary cancer test to understand their inherited risk of cancer. Its pipeline focus on advancing screening and diagnostic products, including risk assessment, screening and prevention, early disease diagnosis, adjuvant and/or neoadjuvant disease treatment, metastatic disease treatment selection, and recurrence monitoring. The company has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University, as well as Freenome Holdings, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.

Latest reported EXAS revenue for 2025-09-30 was $850.7M. Net income was -$122.0M. Revenue was up 4.9% from 2025-06-30 to 2025-09-30. EXAS currently screens at market cap $20.03B.

Use this EXAS page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the EXAS quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the EXAS SEC filings page. Lician reads the product cache first so this HTML stays unique to EXACT Sciences Corporation even when a live quote feed is slow.